| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
MMV676584 targets specific proteins or enzymes in Plasmodium parasites, disrupting parasite metabolism or replication within the host. The compound also shows activity against Mycobacterium tuberculosis, indicating additional or alternative targets in bacterial pathogens. Its precise molecular target(s) in Plasmodium and Mycobacterium remain to be fully elucidated, but its broad-spectrum anti-infective activity makes it a valuable tool for drug discovery research.
|
|---|---|
| ln Vitro |
MMV676584 demonstrates potent in vitro activity against Plasmodium falciparum with an IC50 of 1.3 μM for the asexual erythrocytic stage. It shows anti-tuberculosis activity with an IC50 of 0.6 μM against Mycobacterium tuberculosis. The compound also exhibits activity against fungal pathogens associated with eumycetoma. Its in vitro efficacy across multiple pathogen classes highlights its potential as a broad-spectrum anti-infective agent.
|
| ln Vivo |
In vivo activity of MMV676584 is suggested by its inclusion in the MMV Pathogen Box as a novel drug candidate. The compound has been identified as a candidate for eumycetoma, indicating potential for in vivo efficacy against this fungal disease. Further in vivo studies in appropriate animal models of malaria, tuberculosis, and eumycetoma are needed to fully characterize its therapeutic potential and pharmacokinetic-pharmacodynamic relationships.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for MMV676584 are not extensively documented in the literature. As a compound from the MMV Pathogen Box, its activity is typically assessed in phenotypic screens against whole pathogens rather than isolated enzyme targets. Target identification studies may employ chemoproteomic approaches such as affinity pulldown or thermal shift assays to identify the compound's binding partners in Plasmodium or Mycobacterium lysates.
|
| Cell Assay |
In vitro cellular assays for MMV676584 involve culturing Plasmodium falciparum-infected erythrocytes or Mycobacterium tuberculosis cultures in the presence of varying compound concentrations. Anti-malarial activity is assessed by measuring parasite growth inhibition using fluorescence-based or microscopy-based readouts. Anti-tuberculosis activity is evaluated by measuring inhibition of bacterial growth using optical density measurements or colony counting, with IC50 values determined from dose-response curves.
|
| Animal Protocol |
In vivo animal experiments for MMV676584 are not extensively documented in the available literature. If used in animal models, typical protocols would involve administering the compound to Plasmodium-infected mice for malaria efficacy studies, or to M. tuberculosis-infected mouse models for TB efficacy evaluation. Efficacy would be assessed by measuring parasite burden, bacterial load in tissues, or survival rates, with pharmacokinetic parameters also evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for MMV676584 are limited. The compound is soluble in DMSO at 100 mg/mL (317.67 mM). Powder formulations should be stored at -20°C for up to 3 years, and solutions at -80°C for up to 1 year. Its absorption, distribution, metabolism, and excretion (ADME) properties have not been fully characterized. Further pharmacokinetic studies are needed to determine its bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for MMV676584 are limited. As a research compound from the MMV Pathogen Box, comprehensive toxicological studies have not been reported. The compound is for research use only and is not intended for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound, including the use of personal protective equipment.
|
| References |
[1]. Wilson Lim, et al. Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma. PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006437.
[2]. Clinton G L Veale, et al. Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease. ChemMedChem. 2019 Feb 19;14(4):386-453. |
| Additional Infomation |
MMV676584 (CAS#: 750621-19-3) has the molecular formula C12H8ClFN2OS2 and a molecular weight of 314.79. Its IUPAC name is 3-chloro-N-(4,5-dihydrothiazol-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide. The compound is also known as WAY-606264. It is sourced from the Medicines for Malaria Venture (MMV) Pathogen Box and is used in drug discovery research for malaria, tuberculosis, and eumycetoma.
|
| Molecular Formula |
C12H8CLFN2OS2
|
|---|---|
| Molecular Weight |
314.786122322083
|
| Exact Mass |
313.975
|
| CAS # |
750621-19-3
|
| PubChem CID |
2386708
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WIYIHXHWMONCNB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H8ClFN2OS2/c13-9-7-2-1-6(14)5-8(7)19-10(9)11(17)16-12-15-3-4-18-12/h1-2,5H,3-4H2,(H,15,16,17)
|
| Chemical Name |
3-chloro-N-(4,5-dihydro-1,3-thiazol-2-yl)-6-fluoro-1-benzothiophene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (397.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1767 mL | 15.8836 mL | 31.7672 mL | |
| 5 mM | 0.6353 mL | 3.1767 mL | 6.3534 mL | |
| 10 mM | 0.3177 mL | 1.5884 mL | 3.1767 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
